Document is current
Any future updates will be listed below
-
Authors
Huibers, Anne
Leong, Stanley P.
Kashani-Sabet, Mohammed
White, Richard L. Jr.
Vetto, John
Schneebaum, Schlomo
O’Donoghue, Cristina
Howard, Harrison
Avisar, Eli
Namm, Jukes P.
Kosiorek, Heidi
Faries, Mark
Karakousis, Giorgos
Zager, Jonathan S.
Olofsson Bagge, Roger
,
-
Funding
Funding for this research was provided by:
University of Gothenburg
- License Information
-
More Information
Article History
Received: 27 December 2024
Accepted: 9 February 2025
First Online: 10 March 2025
Disclosure
: Mohammed Kashani-Sabet had an ownership interest in Melanoma Diagnostics and DNARx, and has acted as a paid advisor for Bristol-Myers Squibb and Replimune for work performed outside the current study. John Vetto is a speaker for Castle Biosciences. Mark Faries is on advisory boards for Bristol Myers Squibb, Merck, Regeneron, and Replimune. Giorgos Karakousis is on advisory boards of Merck, Bristol-Myers Squibb, Merck for institutional research support. Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag), SkyLineDx, and NeraCare GmbH, as well as speaker honoraria from Roche, Pfizer, and Pierre-Fabre, has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche, and Sanofi Genzyme, and is a shareholder in SATMEG Ventures A. The remaining authors have no conflicts of interest.
